Highlights

• Zydus Lifesciences increased its equity share buyback price to INR 1,260 per share.
• The company reduced total buyback shares to 87.30 lakh equity shares from 95.65 lakh shares.
• The revised buyback proposal was approved by the Buyback Committee on May 27, 2026.

Zydus Lifesciences Limited (NSE:ZYDUSLIFE) announced an addendum to its public announcement regarding the ongoing equity share buyback program. The company informed stock exchanges that its Buyback Committee approved revisions to the buyback terms during a meeting held on May 27, 2026.

The disclosure was submitted to both BSE Limited and National Stock Exchange of India Limited under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Source: Analysis by Kalkine 

Buyback Price Revised Upward

As part of the revised proposal, Zydus Lifesciences increased the buyback price from INR 1,150 per equity share to INR 1,260 per equity share. The buyback will continue to be conducted through the tender offer route in accordance with applicable regulations.

The company had earlier announced plans to repurchase fully paid-up equity shares with a face value of INR 1 each. The revised buyback price reflects an increase of INR 110 per share compared with the earlier announced level.

The aggregate buyback size remains capped at INR 1,100 crore, according to the filing submitted by the company.

Maximum Buyback Shares Reduced

Alongside the increase in buyback price, the company reduced the maximum number of equity shares proposed to be bought back.

The revised number of shares now stands at 87,30,158 equity shares, compared with the earlier proposed 95,65,217 equity shares. According to the filing, the revised quantity represents up to 0.87% of the total paid-up equity share capital of the company.

The reduction in the total number of shares follows the upward revision in the buyback price while maintaining the previously announced aggregate buyback size.

Addendum to Public Announcement

The company stated that an addendum to the public announcement will be published in Financial Express in English and Gujarati editions, along with Jansatta in Hindi editions.

According to the disclosure, the addendum will also be available on the company’s official website, the website of the manager to the buyback, and the SEBI website during the buyback period.

The company clarified that all capitalized terms used in the communication would carry the meanings assigned in the original public announcement.

Buyback Approved Under SEBI Regulations

The buyback process is being undertaken in accordance with the Companies Act, 2013 and the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018.

The company noted that the revisions were approved pursuant to Regulation 5(via) of the Buyback Regulations. The buyback is proposed on a proportionate basis through the tender offer mechanism.

The filing was signed by Dhaval N. Soni, Company Secretary and Compliance Officer of Zydus Lifesciences.

Key Risks Investors Should Track

• Regulatory approvals or compliance changes may affect the buyback process.
• Market volatility may influence shareholder participation in the tender offer.
• Changes in liquidity conditions could affect stock price movement during buyback.
• Reduced buyback shares may impact investor expectations regarding participation ratio.

Summary

Zydus Lifesciences (NSE:ZYDUSLIFE) revised its share buyback proposal by increasing the buyback price to INR 1,260 per equity share from INR 1,150. At the same time, the company reduced the maximum number of shares proposed for repurchase to 87.30 lakh equity shares from 95.65 lakh shares. The aggregate buyback size remains capped at INR 1,100 crore under the tender offer route in accordance with SEBI regulations.

FAQs

Q: What is the revised buyback price announced by Zydus Lifesciences?
A: Zydus Lifesciences increased the buyback price to INR 1,260 per equity share from INR 1,150 previously announced.

Q: How many shares will Zydus Lifesciences buy back after the revision?
A: The company revised the buyback quantity to 87,30,158 equity shares under the updated proposal.

Q: What is the total size of the Zydus Lifesciences buyback program?
A: The aggregate size of the buyback remains capped at INR 1,100 crore under the tender offer mechanism.